Methods For Treating Tumors Using Anti-Angiogenic Compounds
Description of Invention:
Angiogenesis is the process of tumor vascularization which involves both positive and negative regulators. It is recognized as a critical process in tumor progression and is essential for the growth and persistence of solid tumors and their metastases. This vascularization is induced by a variety of pro-angiogenic factors, which are balanced against naturally occurring negative regulators of angiogenesis, such as endostatin.
Endostatin is a protein derived from the cleavage of the precursor collagen XVIII. It is an endogenous inhibitor of angiogenesis and tumor growth that can inhibit angiogenesis and can induce dormancy or regression of large tumors in mice. Furthermore, endostatin does not induce acquired drug resistance, a problem associated with chemotherapy and other cytochemical therapies. However, difficulties in producing sufficient recombinant endostatin for widespread clinical use has presented significant obstacles in developing an endostatin therapy model.
The present invention describes a method of delivering endostatin as well as other inhibitors of angiogenesis by administering an adenovirus vector carrying a modified endostatin gene. This method allows the host to produce high levels of secreted endostatin systemically and in the local tumor environment. This invention obviates the need to systemically administer recombinant protein and may allow for more efficient treatment strategies.
Inventors:
Steven K. Libutti and Andrew L. Feldman (NCI)
Patent Status:
DHHS Reference No. E-271-1998/0 --
U.S. Provisional Application No. 60/133,243 filed 07 May 1999
PCT Application No. PCT/US00/12392 filed 05 May 2000, which published as WO 00/068379 on 16 Nov 2000
U.S. Patent Application No. 10/031,008 filed 07 Nov 2001
Portfolios: Cancer
Cancer -Therapeutics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
